News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,305 Results
Type
Article (14227)
Company Profile (282)
Press Release (252796)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79518)
Career Advice (153)
Deals (13227)
Drug Delivery (35)
Drug Development (50454)
Employer Resources (31)
FDA (5721)
Job Trends (5131)
News (144414)
Policy (10031)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (914)
Accelerated approval (2)
Adcomms (12)
Allergies (51)
Alliances (21655)
ALS (63)
Alzheimer's disease (842)
Antibody-drug conjugate (ADC) (89)
Approvals (5741)
Artificial intelligence (119)
Autoimmune disease (17)
Automation (5)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (42)
Biotechnology (232)
Bladder cancer (47)
Brain cancer (20)
Breast cancer (146)
Cancer (1364)
Cardiovascular disease (116)
Career advice (133)
Career pathing (2)
CAR-T (110)
Cell therapy (314)
Cervical cancer (8)
Clinical research (40984)
Collaboration (518)
Compensation (253)
Complete response letters (13)
COVID-19 (1034)
CRISPR (39)
C-suite (154)
Cystic fibrosis (76)
Data (1424)
Denatured (11)
Depression (29)
Diabetes (130)
Diagnostics (1294)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (82)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (88)
Earnings (29738)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48296)
Executive appointments (440)
FDA (6385)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (485)
Gene editing (93)
Generative AI (10)
Gene therapy (240)
GLP-1 (363)
Government (1078)
Grass and pollen (2)
Guidances (19)
Healthcare (6593)
Huntington's disease (22)
IgA nephropathy (22)
Immunology and inflammation (88)
Indications (18)
Infectious disease (1099)
Inflammatory bowel disease (111)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (62)
Interviews (17)
IPO (7269)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (5)
Layoffs (205)
Leadership (3)
Legal (1386)
Liver cancer (31)
Lung cancer (194)
Lymphoma (89)
Machine learning (2)
Management (7)
Manufacturing (126)
MASH (50)
Medical device (2594)
Medtech (2595)
Mergers & acquisitions (6277)
Metabolic disorders (376)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (63)
Neuropsychiatric disorders (23)
Neuroscience (1233)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1627)
Now hiring (22)
Obesity (191)
Opinion (102)
Ovarian cancer (61)
Pain (41)
Pancreatic cancer (53)
Parkinson's disease (119)
Partnered (8)
Patents (123)
Patient recruitment (69)
Peanut (35)
People (25591)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14475)
Phase II (19066)
Phase III (12055)
Pipeline (775)
Policy (43)
Postmarket research (852)
Preclinical (6079)
Press Release (30)
Prostate cancer (57)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (286)
Real estate (1418)
Recruiting (12)
Regulatory (8601)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (57)
Series A (95)
Series B (60)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1431)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1972)
State (1)
Stomach cancer (4)
Supply chain (20)
Tariffs (5)
The Weekly (36)
United States (12673)
Vaccines (208)
Venture capitalists (30)
Weight loss (108)
Women's health (15)
Worklife (2)
Date
Today (15)
Last 7 days (263)
Last 30 days (1408)
Last 365 days (19574)
2025 (5478)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27807)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (41)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17251)
Australia (2928)
California (3688)
Canada (1098)
China (332)
Colorado (142)
Connecticut (147)
Delaware (93)
Europe (37127)
Florida (443)
Georgia (115)
Idaho (16)
Illinois (219)
India (10)
Indiana (90)
Iowa (1)
Japan (73)
Kansas (61)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (459)
Massachusetts (2917)
Michigan (70)
Minnesota (142)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (929)
New Mexico (12)
New York (997)
North Carolina (535)
North Dakota (4)
Northern California (1627)
Ohio (109)
Oklahoma (9)
Oregon (21)
Pennsylvania (699)
Puerto Rico (5)
Rhode Island (16)
South America (208)
South Carolina (4)
Southern California (1431)
Tennessee (25)
Texas (423)
Utah (50)
Virginia (74)
Washington D.C. (30)
Washington State (337)
Wisconsin (14)
267,305 Results for "abeona therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
March 4, 2025
·
2 min read
FDA
FDA Action Alert: Regeneron, Sanofi and Abeona
Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for Regeneron, one with partner Sanofi.
April 14, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 1, 2025
April 2, 2025
·
3 min read
Press Releases
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
March 20, 2025
·
9 min read
Press Releases
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 3, 2025
March 4, 2025
·
3 min read
Policy
Abeona Therapeutics Provides Regulatory Update on Pz-cel
Abeona Therapeutics Inc. announced a regulatory update for prademagene zamikeracel.
April 22, 2024
·
6 min read
BioMidwest
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its senior management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. Eastern Time.
May 28, 2024
·
3 min read
Press Releases
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 3, 2025
February 4, 2025
·
3 min read
Deals
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock.
May 3, 2024
·
5 min read
Business
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2024 and recent corporate progress.
May 15, 2024
·
8 min read
1 of 26,731
Next
